1609200-16-9

Upstream product

• 1609200-15-8 C₃₁H₃₆N₂O₄ 
• 1609200-14-7 (4aR,11cS)-4a-allyl-7-(tert-butoxycarbonyl)-2,3,4,4a,5,6,7,11c-octahydro-1H-pyrido[3,2-c]carbazole 
• 1609200-13-6 (4aR,11cS)-4a-allyl-2,3,4,4a,5,6,7,11c-octahydro-1H-pyrido[3,2-c]carbazole 
• 1609200-12-5 (R)-2-{2-(3-allyl-2-oxo-piperidin-3-yl)ethyl}-1H-indole 
• 1609200-10-3 2-{2-(3-allyloxycarbonyl-1-benzoyl-2-oxopiperidin-3-yl)ethyl}-1-tert-butoxycarbonyl-1H-indole 
• 1609200-11-4 (R)-2-{2-(3-allyl-1-benzoyl-2-oxopiperidin-3-yl)ethyl}-1-tert-butoxycarbonyl-1H-indole 
• 1609200-09-0 1-(tert-butoxycarbonyl)-2-(2-iodoethyl)-1H-indole 
• 1334651-33-0 tert-butyl 2-(2-hydroxyethyl)-1H-indole-1-carboxylate 
• 1318759-39-5 2-(2-(tetrahydro-2H-pyran-2-yloxy)ethyl)-1H-indole 
• 120-72-9 indole 

Relevant academic research and scientific papers

Total synthesis of (+)-kopsihainanine A

Total synthesis of (+)-kopsihainanine A was accomplished on the basis of (i) Stoltz's enantioselective decarboxylative asymmetric allylation and (ii) the proposed biogenetic pathway from the related alkaloid, kopsihainanine B. In addition, HPLC analysis of the synthetic (+)-kopsihainanine A confirmed its ee to be 99% with [α]30D = 25.35. the Partner Organisations 2014.